Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDNASDAQ:BMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$142.67-4.9%$146.39$111.09▼$169.37$8.66B0.61470,607 shs576,851 shsBMRNBioMarin Pharmaceutical$60.26-10.7%$67.95$59.99▼$94.85$11.50B0.31.86 million shs3.55 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-4.94%-7.76%-8.46%+1.62%-4.57%BMRNBioMarin Pharmaceutical-10.70%-15.65%-15.35%-9.83%-30.56%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S2.9371 of 5 stars4.51.00.00.03.51.70.6BMRNBioMarin Pharmaceutical4.8741 of 5 stars4.43.00.03.33.52.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.93Moderate Buy$204.6443.44% UpsideBMRNBioMarin Pharmaceutical 2.71Moderate Buy$94.0055.99% UpsideCurrent Analyst Ratings BreakdownLatest ASND and BMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.002/25/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$170.00 ➝ $200.002/24/2025BMRNBioMarin PharmaceuticalOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$98.002/20/2025BMRNBioMarin PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$94.002/20/2025BMRNBioMarin PharmaceuticalCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$81.00 ➝ $82.002/20/2025BMRNBioMarin PharmaceuticalScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$78.00 ➝ $80.002/20/2025BMRNBioMarin PharmaceuticalRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$70.00 ➝ $70.002/20/2025BMRNBioMarin PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.002/20/2025BMRNBioMarin PharmaceuticalUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$109.00 ➝ $113.002/20/2025BMRNBioMarin PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$122.00 ➝ $126.002/20/2025BMRNBioMarin PharmaceuticalBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$99.00 ➝ $103.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$363.64M23.81N/AN/A($1.88) per share-75.89BMRNBioMarin Pharmaceutical$2.85B4.03$2.85 per share21.17$29.69 per share2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$7.10N/A594.46N/A-104.54%N/A-39.23%5/1/2025 (Estimated)BMRNBioMarin Pharmaceutical$167.65M$2.2027.3913.820.6114.96%9.91%7.65%4/23/2025 (Estimated)Latest ASND and BMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AASNDAscendis Pharma A/S-$1.56N/AN/AN/A$98.56 millionN/A4/23/2025N/ABMRNBioMarin Pharmaceutical$0.95N/AN/AN/A$741.84 millionN/A2/19/2025Q4 2024BMRNBioMarin Pharmaceutical$0.54$0.72+$0.18$0.64$711.05 million$747.31 million2/12/2025Q4 2024ASNDAscendis Pharma A/S-$1.32-$0.68+$0.64-$0.68$115.06 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.170.84BMRNBioMarin Pharmaceutical0.115.332.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABMRNBioMarin Pharmaceutical98.71%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BMRNBioMarin Pharmaceutical1.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01760.69 million36.41 millionOptionableBMRNBioMarin Pharmaceutical3,401190.78 million187.06 millionOptionableASND and BMRN HeadlinesRecent News About These CompaniesClearbridge Investments LLC Sells 35,140 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)April 4 at 4:33 AM | marketbeat.comAllstate Corp Takes $368,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)April 4 at 4:05 AM | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Downgraded by StockNews.com to BuyApril 3 at 11:16 PM | marketbeat.comBioMarin Pharma’s phase 3 PEGASUS trial evaluating Palynziq in adolescents with phenylketonuria meets primary efficacy endpointApril 3 at 7:50 PM | pharmabiz.comPositive pivotal data for Palynziq in adolescentsApril 3 at 7:50 PM | thepharmaletter.comTruist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)April 3 at 7:50 PM | markets.businessinsider.comBioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label ExpansionApril 3 at 3:38 PM | seekingalpha.comBMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric StudyApril 3 at 11:15 AM | zacks.comGroupama Asset Managment Has $6.77 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)April 3 at 6:17 AM | marketbeat.comTrexquant Investment LP Trims Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)April 3 at 6:16 AM | marketbeat.comBioMarin Announces Positive Pivotal Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with PhenylketonuriaApril 3 at 4:41 AM | medindia.netBioMarin: Phase 3 PEGASUS trial of Palynziq met primary endpointApril 3 at 4:41 AM | markets.businessinsider.comPictet Asset Management Holding SA Sells 634,916 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)April 3 at 4:18 AM | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to Buy at StockNews.comApril 3 at 1:27 AM | americanbankingnews.comBioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent PatientsApril 2 at 3:33 PM | finance.yahoo.comBioMarin Pharmaceutical: Promising Growth Driven by Palynziq Success and Pipeline OpportunitiesApril 2 at 2:29 PM | tipranks.comHere's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth StockApril 2 at 10:50 AM | zacks.comIs BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now?April 2 at 10:30 AM | insidermonkey.comBioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with PhenylketonuriaApril 2 at 9:00 AM | prnewswire.comKnott David M Jr Decreases Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)April 2 at 7:26 AM | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Has $9.57 Million Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)April 2 at 4:07 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASND and BMRN Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$142.67 -7.42 (-4.94%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$144.71 +2.04 (+1.43%) As of 04/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BioMarin Pharmaceutical NASDAQ:BMRN$60.26 -7.22 (-10.70%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$60.30 +0.04 (+0.07%) As of 04/4/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
